The primary cardiovascular outcome trials demonstrated the effectiveness of SGLT2 inhibitors in reducing CV mortality and hospitalizations due to heart failure among individuals with T2DM, and secondary findings from these initial trials also indicated a potential up to 40% decrease in the risk of kidney disease progression [26,28]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.